Marketresearchnews

Monday, 21 June 2021

Dissolvable Sutures Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Global dissolvable sutures market is expected to gain prominence over the forecast period (2018-2023). It is estimated that the global dissolvable sutures market is expected to grow at a CAGR ~5.2 % during the forecast period of 2018–2023.

Dissolvable sutures are stitches that doctors and surgeons, use to hold skin, internal organs, blood vessels, and all other tissues of the human body together, after the injury, incision, or surgery. These sutures have an anticipated advantage as they are broken down in the body tissue after a given period, and no foreign material left inside the patient's body.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6081

The market growth is attributed to the increasing aging population, rising occurrence of chronic diseases, increasing healthcare expenditure, growing number of surgeries and burns, and increasing number of hospitals. According to the WHO, an estimate of tens of million people are injured or disabled worldwide every year in road accidents. Additionally, immense technological advancements in material science and increasing occurrences of musculoskeletal diseases are likely to boost the market growth during the forecast period.

Despite the drivers, the development of advanced wound care dressings and availability of alternatives such as surgical staplers and complications such as hemorrhage and leakage, especially in esophageal and colonic anastomosis are a few factors restraining the growth of the dissolvable sutures market. Furthermore, stringent government regulations and increasing preference for minimally invasive surgical procedures are the constraints limiting the market growth.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research.

Primary Research

The extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VP, CEO's, Marketing Director, Business Development Manager and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

Secondary Research

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the global dissolvable sutures market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.

Global Dissolvable Sutures Key Players

Braun Melsungen AG, Boston Scientific Corporation, DemeTECH Corporation, ENDOEVOLUTION LLC, Hu-Friedy Mfg. Co., LLC, Internacional Farmacéutica S.A. De C.V., Johnson & Johnson Services, Inc., Medline Industries, Inc., Medtronic, Péters Surgical, Roboz Surgical Instrument Co., Smith & Nephew, Surgical Specialties Corporation, and Sutures India Private Limited are prominent players in the global dissolvable sutures market.

Segmentation

The global dissolvable sutures market is segmented on the basis of type, application, and end-user.

On the basis of type, the market is classified as natural dissolvable sutures and synthetic dissolvable sutures. Natural dissolvable sutures are further segmented as catgut plain sutures and catgut chromic sutures. Synthetic dissolvable sutures are further sub-segmented into polyglycolic acid sutures - coated and braided suture, polyglactin 910 sutures - coated and braided suture, poliglecaprone sutures - monofilament suture, and polydioxanone sutures - monofilament suture.

The global dissolvable sutures market on the basis of application is segmented into cardiovascular surgeries, general surgeries, gynecological surgeries, orthopedic surgeries, ophthalmic surgeries, and others.

The global dissolvable sutures market on the basis of end-user is segmented as ambulatory surgical centers, hospitals, clinics, and others.

Geographically, the global dissolvable sutures market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American dissolvable sutures market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.

The European dissolvable sutures market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.

The Asia Pacific dissolvable sutures market is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia Pacific.

The Middle Eastern and African dissolvable sutures market is segmented into the Middle East and Africa.

Regional Market Summary

The global dissolvable sutures market consists of four regions, namely, Americas, Europe, Asia Pacific, and the Middle East and Africa. North America holds the highest market share in the global dissolvable sutures market owing to the higher adoption of technologically advanced products for surgical procedures in the region, increase in the prevalence of various chronic diseases, and the development of the wound management sector. In addition, according to the Centers for Disease Control and Prevention, in 2015, an approximate 2.8 million people were hospitalized due to injuries in the United States.

Europe holds the second position in the global dissolvable sutures market. The availability of funds for research, huge patient population, increasing healthcare expenditure, and government support for research and development drive the European market. For instance, according to the National Statistics in 2015, the healthcare spending in the U.K. reached 271.6 USD billion in 2015 from 262.2 USD billion in 2014. Furthermore, the presence of developed countries such as Germany and the U.K. within the region is expected to fuel the market growth during the forecast period.

Asia Pacific is experiencing the fastest growth for the global dissolvable sutures market owing to the increasing prevalence of cardiac diseases, rising obese pool, increasing cases of burns, and geriatric population. India and China dominate the market for dissolvable sutures in the Asia Pacific region. According to the World Health Organization, over 1,000,000 people are moderately or severely burnt every year in India. Additionally, the availability of significant growth opportunities for prominent players due to improved healthcare infrastructure, rise in healthcare awareness, and development in the medical tourism industry are also contributing to the growth of the market.

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Industry Insights

April 2017, Medtronic Plc signed an agreement to divest a portion of its patient monitoring and recovery division to Cardinal Health for 6.1 USD billion. In this agreement, the company intends to include 17 dedicated manufacturing facilities among the product line such as dental/animal health, chart paper, wound care, incontinence, electrodes, and sharp safety offerings.

Moreover, the Surgigut gut sutures by Medtronic are made up of purified connective tissue derived serosal layer of bovine intestines. The other Medtronic dissolvable sutures include VELOSORB fast braided absorbable sutures, CAPROSYN monofilament absorbable suture, and POLYSORB braided absorbable sutures.

January 2016, Surgical Specialties Corporation acquired FSSB Chirurgische Nadein GMBH, a German manufacturer of surgical needles and sutures. With the acquisition, the company expanded its surgical products portfolio. Moreover, in September 2015, Smith & Nephew launched NASASTENT Dissolvable Nasal Dressing, a structural intranasal splint for use in sinus surgery.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/dissolvable-sutures-market-6081

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Cruciate Ligament Diagnosis & treatment Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

The cruciate ligament treatment includes numerous surgical techniques that involve reconstruction and replacement of the knee and related ligaments. The upsurge in obese population is considered as a chief factor emphasizing the growth of this market. Obesity in the aging population has been reported to directly increase the risk of degenerative bone disorders, such as osteoporosis and osteoarthritis, additionally resulting in target injury and fracture owing to the extra pressure exerted on joints. Later, increasing number of people who have osteoporosis is expected to generate demand for the market.

However, the lack of availability of skilled professionals and the high cost of treatment procedures may hinder the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6080

Many prominent players in the market have incorporated into acquisitions, mergers, and continuous launches of quality systems to hold the market position. The firms are focusing on mergers and acquisitions to enhance their product portfolio. For instance, the acquisition of Cayenne Medical by Zimmer Biomet was involved in reconstruction solutions and advanced soft tissue repair for knee, shoulder, and extremities. Besides, companies are involving into geographic expansions to cater to the untargeted population for tissue repair and surgeries.

Regional Analysis

The global cruciate ligament diagnosis and treatment market consists of four regions, namely, Americas, Europe, Asia Pacific, and the Middle East and Africa.

The American region holds the major share of the global cruciate ligament diagnosis and treatment market, owing to the existing well-established healthcare system, increasing prevalence of degenerative bone disorder cases, and technological advancements. Sports such as soccer, football, and skiing have been reported to be high-risk sports that can cause injury to the ACL when compared to other sports activities. For instance, due to increasing occurrences of ACL injuries, nearly 100,000 ACL reconstructions are performed each year as per a report published by PubMed.

Europe holds the second position in the global cruciate ligament diagnosis and treatment market. It is expected that the government support towards research and development expenditure and rising prevalence of chronic bone diseases are likely to drive the European cruciate ligament diagnosis and treatment market.

The Asia Pacific cruciate ligament diagnosis and treatment market consist of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the Rest of Asia Pacific. Japan is the largest market for cruciate ligament diagnosis and treatment due to an increase in the prevalence of cancer and demand for cruciate ligament diagnosis and treatment techniques. In China, factors responsible for the market growth are rising geriatric population with osteoporosis diseases and availability of low-cost diagnostic and treatment options.

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Segmentation

The global cruciate ligament diagnosis and treatment market is segmented on the basis of type, injury type, product, diagnosis, treatment, and end-user.

Based on type, the global cruciate ligament diagnosis and treatment market is classified as Posterior Cruciate Ligament (PCL) and Anterior Cruciate Ligament (ACL).

The segments for injury type for the global cruciate ligament diagnosis and treatment market are classified as grade I, grade II, and grade III.

On the basis of product, the global cruciate ligament diagnosis and treatment market is classified as cemented implants, cement-less implants, partial implants, and revision implants.

Based on indication, the global cruciate ligament diagnosis and treatment market is classified as osteoarthritis, rheumatoid arthritis, trauma, and others.

The diagnosis segment for the global cruciate ligament diagnosis and treatment market is classified as imaging and others. The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others.

Based on treatment, the global cruciate ligament diagnosis and treatment market is classified as surgery, therapies, devices, and others. Surgery can be further sub-divided into arthroscopy, Anterior Cruciate Ligament (ACL) reconstruction, and others. The therapies include rehabilitation and physical therapies. The devices include elastic bandages and others.

On the basis of end-user, the global cruciate ligament diagnosis and treatment market is classified as hospitals, orthopedic clinics, Ambulatory Surgical Center (ASC), and others.

Global Cruciate Ligament Diagnosis & Treatment Key Players

Stryker Corporation (U.S.), Arthrex, Inc. (U.S.), Zimmer Biomet (U.S.), DePuy Synthes, Inc. (U.S.), CONMED Corporation (U.S.), Smith & Nephew plc. (U.S.), DJO Global Inc. (U.S.), Breg, Inc. (U.S.), Bauerfeind AG (Germany), Össur hf. (Iceland), DeRoyal Industries, Inc. (U.S.), BSN Medical GmbH (Germany), 3M Company (U.S.), Otto Bock Healthcare GmbH (Germany), THUASNE SA (France), medi GmbH & Co. KG (Germany), DeRoyal Industries Inc. (U.S.), Corin Group (UK), United Orthopedic Corporation (Taiwan), Exactech Inc. (U.S.), Japan Medical Dynamic Marketing (Japan), Tornier Inc. (U.S.), and others are some prominent players in this market.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/cruciate-ligament-diagnosis-treatment-6080

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Pain Management Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

The global pain management market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the pain management market is expected to register a CAGR of 6.0% during the forecast period of 2018–2023.

Pain is considered as a clinical, social, and economic burden in communities around the world, as chronic pain is associated with various health conditions. The increasing prevalence of pain pushes the demand for better diagnosis and treatments.

Notably, the market is expected to expand in the near future due to increasing technological advancements. The increasing occurrences of chronic pain conditions are continuously motivating marketers to come up with more technologically advanced products. For instance, a new noninvasive neuromodulation device, Stimpod NMS460 was introduced by the Xavant Technology to treat the chronic intractable pain. The device has received an FDA approval on August 01, 2017.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5975

According to a study published in the Current Pain and Headache Reports Journal in 2016, it was found that Peripheral Nerve Stimulation (PNS) is a widely accepted treatment procedure for chronic pain. The StimRouter neuromodulation system by Bioness, Inc is a PNS technology-based device specifically designed to treat chronic pain. The device received the FDA approval in 2015.

Various other factors such as increasing geriatric population, improved reimbursement policies in developed countries, the increasing prevalence of cancer pain, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global pain management market.

Despite these drivers, there are some issues associated with the pain management market. The high cost associated with the technology, lack of skilled or trained physicians, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

Key Players

Some of the key players in the global pain management market are Abbott Laboratories, Abbvie, Allergan, Astellas Pharma, AstraZeneca plc, Bayer AG, Codman And Shurtleff, Inc, DJO Global LLC, Eli Lilly & Company, Endo Health Solutions, F. Hoffmann-La Roche Ltd, Forest Laboratories, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Mallinckrodt plc, Medtronic PLC, ST. Jude Medical, Inc., Boston Scientific Corporation, Pfizer Inc., Halyard Health, Inc., Smiths Medical, B. Braun Melsungen AG, Neurotech Na, Inc., Becton, Dickinson and Company, Nevro Corp., Merck & Co. Inc., Novartis AG, Purdue Pharma LP, Sanofi, Stryker Corporation, Teva Pharmaceuticals, and others.

Intended Audience

Pharmaceutical Companies
Medical Devices Companies
Research and Development (R&D) Companies
Government Research Institutes
Academic Institutes and Universities

Segmentation

The global pain management market is segmented on the basis of type of pain management devices, type of pain management drugs, indication, mode of purchase, and end-user.

On the basis of type of pain management devices, the market is classified as neurostimulation devices, analgesic infusion pumps, and ablation devices. The neurostimulation devices are further segmented into Transcutaneous Electrical Nerve Stimulation (TENS) devices and Spinal Cord Stimulation (SCS) devices. Ablation devices are further segmented into RF ablation devices and cryoablation devices.

On the basis of type of pain management drugs, the market is classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), anticonvulsants, anesthetics, opioids, antimigraine agents, antidepressants, and others. The opioids segment is further classified as oxycodones, hydrocodone, tramadol, morphine, codeine, fentanyl, meperidine, methadone, and others.

On the basis of indication, the market is classified as neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, fibromyalgia, chronic back pain, arthritic pain, migraine, post-operative pain, and others.

On the basis of the mode of purchase, the market is classified as over the counter and prescription-based.

On the basis of end-user, the market is classified as hospitals and clinics, pharmaceutical companies, medical device companies, research and academic institutes, and others.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/pain-management-market-5975

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Neurocutaneous Disorder Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

Market Scenario

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5937

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.

Global market for neurocutaneous disorders is expected to have a CAGR of approximately 6.5% during 2017 to 2023.

Intended Audience

Clinical and diagnostic labs
Pharmaceutical and biotechnology companies
Regulatory bodies
Medical device companies
Healthcare providers
Research and consulting firms
Venture capitalists and investors

Segmentation

The global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the global neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The global neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Key Players

Some of the key players in the global neurocutaneous disorder market are Valeant Pharmaceuticals International, Inc. (U.S.), Allergan (U.S.), Syneron Medical Ltd (U.S.), Medtronic Plc (U.S.), Cutera, Inc. (U.S.), St Jude Medical, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories Inc. (U.S.), UCB S.A. (Belgium), Sanofi SA (France), Shire Plc (Ireland), F. Hoffmann-La Roche AG (Switzerland), Aleva Neurotherapeutics SA (Switzerland), Johnson & Johnson (U.S.), and others.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/neurocutaneous-disorder-market-5937

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Paroxysmal Supraventricular Tachycardia Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.

The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5918

The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.

Intended Audience

Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers
Paroxysmal Supraventricular Tachycardia Treatment Providers
Imaging Device Manufacturers
Hospitals and Clinics
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities
Market Research and Consulting Service Providers
Potential Investors

Segmentation

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).

On the basis of diagnosis, the Global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.

On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.

On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

Regional Analysis

The global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.

Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of this market.

Key Players

Some of the key players in the global Paroxysmal Supraventricular Tachycardia (PSVT) market are GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others

Browse more details of Report @ https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Obesity Treatment Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5872

The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.

Intended Audience

Pharmaceutical Companies
Biotechnological Institutes
Government and Private Laboratories
Research and Development (R&D) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers

Segmentation

The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, and others.

Key players

Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/obesity-treatment-market-5872

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Delirium Market Industry Production and Demand, Competition News and Trends Forecasts to 2027

Delirium is a neurological (nervous system) condition and a serious disturbance in mental abilities that causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as older age, exposure to certain medications, alcohol abuse, surgery or other medical procedures, factors such as exposure to toxic or infectious agents, physical trauma, diet, and behavioral and occupational factors.

The global delirium market is majorly driven by the increasing prevalence of neurological disorders and increasing older population leading to rise in patient population. Additionally, increasing government initiatives, increasing programs to create awareness, and market players offering advanced products are likely to drive the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5850

According to the United Nations, in 2017 approximately over 962 million population was aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This rising aging population is likely to propel the growth of global delirium market. Lack of awareness regarding the treatment is likely to hamper the growth of the market.

The Global Delirium Market is expected to grow at a CAGR of 6% during the forecast period.

Segments

The global delirium market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into hyperactive, hypoactive, and mixed.

On the basis of diagnosis, the market is segmented into laboratory tests, imaging tests, and physical examination. On the basis of laboratory tests, it is further sub-segmented into blood tests and urine tests. On the basis of imaging tests, it is further sub-segmented into brain-imaging tests.

On the basis of treatment, the market is segmented into antipsychotics and supportive care. On the basis of treatment, antipsychotics is further sub-segmented into risperidone, olanzapine, and quetiapine.

On the basis of end-user, the market is segmented into specialty centers, hospitals, and research centers.

Regional Analysis

The North American delirium market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing prevalence of delirium affected the population, along with the increasing older population is likely to drive the market. Additionally, the growing healthcare infrastructure along with the increasing government support is likely to enhance the growth of delirium market in North America. For instance, according to the National Institute of Mental Health, in 2016, around 6.75 of adults in the U.S. were reported to have undergone depression.

Europe is the second largest market and holds a healthy share in the global delirium market. The European market is expected to grow at a strong growth rate during the forecast period owing to the accessibility of advanced treatment facilities and rising skilled medical professionals along with the growing need for better healthcare set-up. Furthermore, the increasing older population, along with growing inclination towards sedentary lifestyle are driving the growth of the delirium market.

Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases and infections is the major driver for the market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. The increasing awareness regarding health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and rise in the standard of living are driving the growth of the delirium market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the rise in healthcare development and rising demand for availability of specialty care centers.

Key Players

Some of the key players in the Delirium market are Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Novartis AG, Pfizer, Inc., Regenstrief Institute, Inc., and Air Liquide Sante International, among others.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com